Bringing the fundamentals into focus…
Back to Sarepta Therapeutics, Inc.
How Sarepta Therapeutics, Inc. stacks up
SRPT · against 404 other Healthcare companies of similar size
Profitability
32/ 100
Below the middle of the pack.
Ranked #291 of 405 · scores higher than 27% of peers
Bars: peers in each 10-point band of the profitability score42 peers with a profitability score of 30–39, including SRPT · Click a bar to see the companies
Why profitability scores 32?
Weighted metrics compared with all Healthcare companies.Mainly because of its operating margin and return on assets, which are weaker than most Healthcare peers.
- a thinner operating margin: weaker than 81% of peers. Operating margin: -29.9% vs peer median 7.1%
- a lower return on assets: weaker than 63% of peers. Return on assets: -1.1% vs peer median 1.7%
- a higher return on invested capital: stronger than 71% of peers. Return on invested capital: 11.3% vs peer median 4.7%
Metric by metric
Position: dot = SRPT, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | SRPT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 381 reported | 11.3% | 5.8% | 69% | 33% | |
| Operating marginHigher is better · 374 reported | -29.9% | 8.0% | 16% | 33% | |
| Return on assetsHigher is better · 387 reported | -1.1% | 2.0% | 33% | 33% | |
| Return on equityHigher is better · 372 reported | -9.5% | 4.8% | 28% | Context only | |
| Gross marginHigher is better · 419 reported | 19.1% | 47.7% | 24% | Context only |
Ranking by profitability score
Top 5 and the companies ranked around SRPT| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 321.5B INR (≈$3.9B) | 100 | 70 | |
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 5 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 289 | 1.6B USD | 33 | 43 | |
| 291 | 14.8B CNY (≈$2.1B) | 32 | 23 | |
| 291 | 17.6B CNY (≈$2.5B) | 32 | 11 | |
| 291 | 1.1B USD | 32 | 32 | |
| 291 | 2.0B USD | 32 | 44 | |
| 291 | 1.6B USD | 32 | 29 | |
| 296 | 24.9B CNY (≈$3.5B) | 31 | 38 | |
| 296 | 8.9B HKD (≈$1.1B) | 31 | 61 | |
| 296 | 1.1B USD | 31 | 43 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score